アジア太平洋地域の気管支拡張症市場、疾患タイプ別（CF気管支拡張症および非CF気管支拡張症）、重症度（軽度から中等度および中等度から重度）、タイプ別（診断および治療）、薬剤タイプ別（ブランドおよびジェネリック）、投与経路別（経口、非経口および吸入）、エンドユーザー別（病院、診療所、在宅医療およびその他）、流通チャネル別（病院薬局、小売薬局、オンライン薬局、その他）、国別（日本、中国、オーストラリア、インド、韓国、シンガポール、インドネシア、タイ、マレーシア、フィリピン、ベトナムおよびアジア太平洋地域のその他の国）2028年までの業界動向および予測
市場分析と洞察：アジア太平洋地域の気管支拡張症市場
アジア太平洋地域の気管支拡張症市場は、2021年から2028年の予測期間に市場が成長すると予想されています。データブリッジマーケットリサーチは、市場は2021年から2028年の予測期間に6.5％のCAGRで成長し、2028年までに1億8,619万米ドルに達すると分析しています。疾患検査の技術的進歩と喫煙者数およびアルコール消費量の増加は、予測期間における市場の需要を推進する主な原動力です。
気管支拡張症には、安全で効果的な製品に対する需要の高まりが、メーカーによる新製品の市場投入に影響を与え、需要が高まるとともに、研究開発への投資の増加が市場の成長につながるという特徴があります。現在、さまざまな研究調査が行われており、メーカーが新しい革新的な気管支拡張症製品を開発するための競争上の優位性が生まれ、気管支拡張症市場にさまざまな機会がもたらされると期待されています。ただし、製品リコールや気管支拡張症の治療における合併症により、予測期間中の市場の成長が抑制されると予想されます。
気管支拡張症は、空気が出入りする経路で感染や炎症が発生し、肺の気道が損傷する病気です。粘液が気道に溜まって詰まり、その領域で細菌が増殖し、気管支拡張症を引き起こします。この粘液が気道に溜まり、早期に診断および治療されない場合、肺に損傷を与える可能性があります。この病気は主に女性に発生し、米国では百日咳の子供は一般的に気管支拡張症を患っていることが記録されています。
気管支拡張症は先天性または後天性があります。後天性は主に乳児や小児に発生し、先天性は成人に発生します。嚢胞性線維症、免疫不全疾患、アレルギー性気管支肺アスペルギルス症、および原発性繊毛運動障害は、気管支拡張症の危険因子の一部です。主に抗生物質と酸素療法が医師によって推奨され、この病気には永久的な治療法がないため、患者は病気と共存しなければなりません。
The Bronchiectasis market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal.
Asia-Pacific Bronchiectasis Market Scope and Market Size
Bronchiectasis market is segmented on the based on the basis of disease type, severity, type, drugs type, route of administration, end user and distribution channel.The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of disease type, the bronchiectasis market is segmented into non-CF bronchiectasis and CF bronchiectasis. In 2021, non-CF bronchiectasis is expected to dominate the bronchiectasis market as it is the most common form of bronchiectasis which has been reported to affect most of the women and adult population.
- On the basis of severity, the bronchiectasis market is segmented into mild to moderate and moderate-to-severe. In 2021, mild to moderate segment is expected to dominate the bronchiectasis market because bronchiectasis is a progressive respiratory disorder which is characterized by abnormally dilated airways, excessive sputum production and recurrent pulmonary infections among other symptoms which can be treated by novel drugs and other therapies.
- On the basis of type, the bronchiectasis market is segmented into treatment and diagnosis. In 2021, treatment segment is expected to dominate the bronchiectasis market because bronchiectasis is the long term chronic disease and affected patient population are largely dependent on drugs in order to lead a healthy life.
- On the basis of drugs type, the bronchiectasis market is segmented into branded and generic. In 2021, branded segment is expected to dominate the bronchiectasis market as most of the companies are engaged in manufacturing of branded drugs. Moreover increasing demand of safe product raises the demand of branded drugs among patient population.
- On the basis of route of administration, the bronchiectasis market is segmented into oral, parenteral, and inhalation. In 2021, inhalation segment is expected to dominate the bronchiectasis market because bronchiectasis is a lung associated inflammatory disease which can rapidly treat with drugs directly targeting lung airways.
- On the basis of end user, the bronchiectasis market is segmented into hospitals, clinics, home healthcare, and others. In 2021, hospitals segment is dominating the bronchiectasis market because hospitals have advanced diagnostic tools used for accurate diagnosis of bronchiectasis. Moreover skilled professionals at hospitals allow effective intravenous drug delivery which acts as another factor boosting the market growth.
- On the basis of distribution channel, the bronchiectasis market is segmented into hospital pharmacy, retail pharmacy and online pharmacy. In 2021, hospital pharmacy is expected to dominate the bronchiectasis market as hospital pharmacy have has wide range of products as per the patients need and demand.
Bronchiectasis Market Country Level Analysis
The bronchiectasis market is analyzed and market size information is provided on the basis of disease type, severity, type, drugs type, route of administration, end user and distribution channel.
The countries covered in the bronchiectasis market report are the Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam and Rest of Asia-Pacific.
Treatment segment in Asia-Pacific region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because bronchiectasis is the life-long disease and required continuous treatment. The overall treatment cost for the bronchiectasis is quite high and now consider in some reimbursement policies. Japan is leading the growth of the Asia-Pacific market and treatment segment is dominating in this country due to technological advancement for the diagnosis and treatment of respiratory diseases.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Technological Advancement for Disease Testing and Increase in Research Regarding the Bronchiectasis Disease are Boosting the Market Growth of Bronchiectasis
Bronchiectasis market also provides you with detailed market analysis for every country growth in bronchiectasis industry with bronchiectasis drugs sales, impact of advancement in the bronchiectasis technology and changes in regulatory scenarios with their support for the bronchiectasis market. The data is available for historic period 2011 to 2019.
Competitive Landscape and Bronchiectasis Market Share Analysis
気管支拡張症市場の競争状況は、競合他社ごとに詳細を提供します。含まれる詳細には、会社概要、会社の財務、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、生産拠点と施設、会社の強みと弱み、製品の発売、製品試験パイプライン、製品の承認、特許、製品の幅と幅、アプリケーションの優位性、技術ライフライン曲線などがあります。提供されている上記のデータ ポイントは、気管支拡張症市場に関連する会社の焦点にのみ関連しています。
気管支拡張症を扱っている主な企業としては、アボット、ハーシル、イノジェン社、ベーリンガーインゲルハイムインターナショナル社、メドラインインダストリーズ社、アチェラボラトリーズファーマセウティコスSA、ヤンセンファーマシューティカルズ社（ジョンソン・エンド・ジョンソン・サービスの子会社）、グラクソ・スミスクライン社、アストラゼネカ社、ファイザー社、メルクシャープアンドドーム社（メルクアンドカンパニー社の子会社）、ノバルティス社、サンファーマシューティカルインダストリーズ社、バイエル社、ドクターレディーズラボラトリーズ社、ビアトリス社、シプラ社などがあります。
世界中の企業によって多くの製品の発売や契約も開始されており、気管支拡張症市場の拡大も加速しています。
- 2018年12月、アストラゼネカは、COPDに伴う重篤な症状の治療を適応とするベベスピエアロスフィア（グリコピロニウム/フォルモテロールフマル酸塩）の承認を取得しました。この製品はすでに、カナダ、米国、オーストラリア、台湾、トルコの規制当局から承認を受けています。この新たな承認により、製品の売上が増加し、同社の収益にプラスの影響を与えています。
- 2018年2月、グラクソ・スミスクライン社は日本でフルナーゼを発売しました。フルナーゼは日本で発売された最初のフルチカゾンプロピオン酸エステルベースの治療薬で、呼吸器疾患に伴う炎症症状の緩和に適応があります。この製品の発売により、同社は日本で気管支拡張症に苦しむ患者の満たされていない需要を満たすことができ、製品売上のプラス増加により同社の収益を押し上げました。
市場プレーヤーによるコラボレーション、製品の発売、事業拡大、賞や表彰、合弁事業、その他の戦略により、気管支拡張症市場における企業市場が強化され、組織が気管支拡張症向けの製品やサービスを改善するメリットももたらされます。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA PACIFIC BRONCHIECTASIS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 DISEASE TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET DRUGS TYPE COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PIPELINE ANALYSIS
5 ASIA PACIFIC BRONCHIECTASIS MARKET: LAWS AND REGULATIONS
6 EPIDEMIOLOGY
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 RISING PATIENT POPULATION SUFFERING FROM BRONCHIECTASIS
7.1.2 GROWING GERIATRIC POPULATION
7.1.3 RISING NUMBER OF SMOKERS AND CONSUMPTION OF ALCOHOL
7.1.4 TECHNOLOGICAL ADVANCEMENT FOR DISEASE TESTING
7.1.5 GROWING DIAGNOSTIC RATE
7.2 RESTRAINTS
7.2.1 HIGH COST OF DIAGNOSTIC TOOLS
7.2.2 PRODUCT RECALLS
7.2.3 INAPPROPRIATE REIMBURSEMENT POLICIES
7.3 OPPORTUNITIES
7.3.1 RISING AWARENESS FOR PREVENTION OF BRONCHIECTASIS IN PRIMARY AND SECONDARY CARE
7.3.2 INCREASING HEALTHCARE EXPENDITURE
7.3.3 INCREASE IN RESEARCH REGARDING THE BRONCHIECTASIS DISEASE
7.3.4 AVAILABILITY OF GENERIC DRUGS IN UNDERDEVELOPED AND DEVELOPING COUNTRIES
7.4 CHALLENGES
7.4.1 COMPLICATIONS IN THE TREATMENT OF BRONCHIECTASIS
7.4.2 LACK OF SKILLED PROFESSIONALS
7.4.3 DIAGNOSITIC CHALLENGES
8 IMPACT OF COVID-19
8.1 PRICE IMPACT
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY CHAIN
8.4 STRATEGIC DECISIONS FOR MANUFACTURERS
8.5 CONCLUSION
9 ASIA PACIFIC BRONCHIECTASIS MARKET, BY DISEASE TYPE
9.1 OVERVIEW
9.2 NON-CF BRONCHIECTASIS
9.3 CF BRONCHIECTASIS
10 ASIA PACIFIC BRONCHIECTASIS MARKET, BY SEVERITY
10.1 OVERVIEW
10.2 MILD TO MODERATE
10.3 MODERATE TO SEVERE
11 ASIA PACIFIC BRONCHIECTASIS MARKET, BY TYPE
11.1 OVERVIEW
11.2 TREATMENT
11.2.1 ANTIBIOTICS
11.2.1.1 MACROLIDE
11.2.1.1.1 AZITHROMYCIN
11.2.1.1.2 CLARITHROMYCIN
11.2.1.1.3 OTHERS
11.2.1.2 AMOXICILLIN
11.2.1.3 CEPHALOSPORIN
11.2.1.3.1 SECOND-GENERATION CEPHALOSPORIN
11.2.1.3.2 THIRD-GENERATION CEPHALOSPORIN
11.2.1.4 AMINOGLYCOSIDE
11.2.1.4.1 GENTAMICIN
11.2.1.4.2 TOBRAMYCIN
11.2.1.5 FLUOROQUINOLONE
11.2.1.6 TETRACYCLINS
11.2.1.7 TRIMETHOPRIM-SULFAMETHOXAZOLE
11.2.1.8 COMBINATION THERAPY
11.2.2 CORTICOSTEROIDS
11.2.2.1 BUDESONIDE
11.2.2.2 FLUTICASONE
11.2.2.3 MOMETASONE
11.2.2.4 FLUNISOLIDE
11.2.2.5 OTHERS
11.2.3 BRONCHODILATORS
11.2.3.1 LONG-ACTING BRONCHODILATORS
11.2.3.1.1 FORMOTEROL
11.2.3.1.2 TIOTROPIUM
11.2.3.1.3 SALMETEROL
11.2.3.1.4 OTHERS
11.2.3.2 SHORT-ACTING BRONCHODILATORS
11.2.3.2.1 ALBUTEROL
11.2.3.2.2 LEVALBUTEROL
11.2.3.2.3 OTHERS
11.2.4 MUCUS THINNING MEDICINE
11.2.4.1 CARBOCISTEINE
11.2.4.2 BROMHEXINE
11.2.4.3 OTHERS
11.2.5 AIRWAY CLEARANCE DEVICES
11.2.5.1 OSCILLATING POSITIVE EXPIRATORY PRESSURE (PEP)
11.2.5.2 INTRAPULMONARY PERCUSSIVE VENTILATION (IPV)
11.2.5.3 POSTURAL DRAINAGE
11.2.5.4 OTHERS
11.2.6 OXYGEN THERAPY
11.2.6.1 OXYGEN CONCENTRATORS
11.2.6.2 COMPRESSED GAS OXYGEN
11.2.6.3 LIQUID OXYGEN
11.2.7 SURGERY
11.2.7.1 BRONCHOSCOPY
11.2.7.2 LUNG TRANSPLANT
11.2.8 OTHERS
11.3 DIAGNOSIS
11.3.1 CHEST CT SCAN
11.3.2 SPUTUM TEST
11.3.3 PULMONARY FUNCTION TEST
11.3.4 X-RAY
11.3.5 OTHERS
12 ASIA PACIFIC BRONCHIECTASIS MARKET, BY DRUGS TYPE
12.1 OVERVIEW
12.2 BRANDED
12.3 GENERICS
13 ASIA PACIFIC BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION
13.1 OVERVIEW
13.2 INHALATION
13.3 ORAL
13.3.1 TABLETS
13.3.2 CAPSULES
13.3.3 OTHERS
13.4 PARENTERAL
13.4.1 INTRAVENOUS
13.4.2 SUBCUTANEOUS
13.4.3 OTHERS
14 ASIA PACIFIC BRONCHIECTASIS MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 CLINICS
14.4 HOME HEALTHCARE
14.5 OTHERS
15 ASIA PACIFIC BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 HOSPITAL PHARMACY
15.3 RETAIL PHARMACY
15.4 ONLINE PHARMACY
15.5 OTHERS
16 ASIA PACIFIC BRONCHIECTASIS MARKET BY GEOGRAPHY
16.1 OVERVIEW
16.2 ASIA-PACIFIC
16.2.1 JAPAN
16.2.2 CHINA
16.2.3 INDIA
16.2.4 AUSTRALIA
16.2.5 SOUTH KOREA
16.2.6 SINGAPORE
16.2.7 MALAYSIA
16.2.8 THAILAND
16.2.9 INDONESIA
16.2.10 PHILIPPINES
16.2.11 VIETNAM
16.2.12 REST OF ASIA-PACIFIC
17 ASIA PACIFIC BRONCHIECTASIS MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
18 SWOT
19 COMPANY PROFILES
19.1 ASTRAZENECA
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 GLAXOSMITHKLINE PLC.
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 TEVA PHARMACEUTICAL USA INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENTS
19.4 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.)
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 NOVARTIS AG
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 PRODUCT PORTFOLIO
19.5.4 RECENT DEVELOPMENTS
19.6 ABBOTT
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENT
19.7 ACHE LABORATORIES FARMACEUTICOS S.A.
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENTS
19.8 BAYER AG
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENTS
19.9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT DEVELOPMENT
19.1 CIPLA INC.
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORTFOLIO
19.10.4 RECENT DEVELOPMENTS
19.11 COVIS PHARMA
19.11.1 COMPANY SNAPSHOT
19.11.2 PRODUCT PORTFOLIO
19.11.3 RECENT DEVELOPMENT
19.12 DR. REDDY’S LABORATORIES LTD.
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENTS
19.13 ELECTROMED, INC.
19.13.1 COMPANY SNAPSHOT
19.13.2 REVENUE ANALYSIS
19.13.3 PRODUCT PORTFOLIO
19.13.4 RECENT DEVELOPMENTS
19.14 HERSILL
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENTS
19.15 HOME OXYGEN COMPANY
19.15.1 COMPANY SNAPSHOT
19.15.2 PRODUCT PORTFOLIO
19.15.3 RECENT DEVELOPMENT
19.16 HORIZON THERAPEUTICS PLC
19.16.1 COMPANY SNAPSHOT
19.16.2 REVENUE ANALYSIS
19.16.3 PRODUCT PORTFOLIO
19.16.4 RECENT DEVELOPMENT
19.17 INOGEN, INC.
19.17.1 COMPANY SNAPSHOT
19.17.2 REVENUE ANALYSIS
19.17.3 PRODUCT PORTFOLIO
19.17.4 RECENT DEVELOPMENTS
19.18 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENT
19.19 MEDLINE INDUSTRIES, INC.
19.19.1 COMPANY SNAPSHOT
19.19.2 PRODUCT PORTFOLIO
19.19.3 RECENT DEVELOPMENTS
19.2 PFIZER INC.
19.20.1 COMPANY SNAPSHOT
19.20.2 REVENUE ANALYSIS
19.20.3 PRODUCT PORTFOLIO
19.20.4 RECENT DEVELOPMENTS
19.21 SUNOVION PHARMACEUTICALS INC. (A SUBSIDIARY OF SUMITOMO DAINIPPON PHARMA CO., LTD.)
19.21.1 COMPANY SNAPSHOT
19.21.2 REVENUE ANALYSIS
19.21.3 PRODUCT PORTFOLIO
19.21.4 RECENT DEVELOPMENTS
19.22 SUN PHARMACEUTICAL INDUSTRIES LTD.
19.22.1 COMPANY SNAPSHOT
19.22.2 REVENUE ANALYSIS
19.22.3 PRODUCT PORTFOLIO
19.22.4 RECENT DEVELOPMENTS
19.23 TRUEDELL MEDICAL INTERNATIONAL
19.23.1 COMPANY SNAPSHOT
19.23.2 PRODUCT PORTFOLIO
19.23.3 RECENT DEVELOPMENTS
19.24 VIATRIS INC.
19.24.1 COMPANY SNAPSHOT
19.24.2 PRODUCT PORTFOLIO
19.24.3 RECENT DEVELOPMENTS
19.25 ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA)
19.25.1 COMPANY SNAPSHOT
19.25.2 REVENUE ANALYSIS
19.25.3 PRODUCT PORTFOLIO
19.25.4 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
表のリスト
LIST OF TABLES
TABLE 1 ASIA PACIFIC BRONCHIECTASIS MARKET, PIPELINE ANALYSIS
TABLE 2 REGULATION IMPOSED BY SEVERAL REGULATORY AGENCIES IN DIFFERENT REGIONS
TABLE 3 HEALTHCARE EXPENDITURE IN ASIA-PACIFIC
TABLE 4 THE PRICE OF X-RAY MACHINE
TABLE 5 ASIA PACIFIC BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 6 ASIA PACIFIC NON-CF BRONCHIECTASIS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 ASIA PACIFIC CF BRONCHIECTASIS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 ASIA PACIFIC BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 9 ASIA PACIFIC MILD TO MODERATE BRONCHIECTASIS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 ASIA PACIFIC MODERATE TO SEVERE BRONCHIECTASIS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 ASIA PACIFIC BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 12 ASIA PACIFIC TREATMENT IN BRONCHIECTASIS MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 13 ASIA PACIFIC TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 14 ASIA PACIFIC TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 15 ASIA PACIFIC TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 16 ASIA PACIFIC TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 17 ASIA PACIFIC TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 18 ASIA PACIFIC TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 19 ASIA PACIFIC TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 20 ASIA PACIFIC TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 21 ASIA PACIFIC TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 22 ASIA PACIFIC TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 23 ASIA PACIFIC TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 24 ASIA PACIFIC TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 25 ASIA PACIFIC TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 26 ASIA PACIFIC DIAGNOSIS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 ASIA PACIFIC DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 28 ASIA PACIFIC BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 29 ASIA PACIFIC BRANDED IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 ASIA PACIFIC GENERICS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 ASIA PACIFIC BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 32 ASIA PACIFIC INHALATION IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 33 ASIA PACIFIC ORAL IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 ASIA PACIFIC ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 35 ASIA PACIFIC PARENTERAL IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 ASIA PACIFIC PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 37 ASIA PACIFIC BRONCHIECTASIS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 38 ASIA PACIFIC HOSPITALS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 ASIA PACIFIC CLINICS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 ASIA PACIFIC HOME HEALTHCARE IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 41 ASIA PACIFIC OTHERS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 ASIA PACIFIC BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 43 ASIA PACIFIC HOSPITAL PHARMACY IN BRONCHIECTASIS MARKET, REGION, 2019-2028 (USD MILLION)
TABLE 44 ASIA PACIFIC RETAIL PHARMACY IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 ASIA PACIFIC ONLINE PHARMACY IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 46 ASIA PACIFIC OTHERS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 47 ASIA PACIFIC BRONCHIECTASIS MARKET, BY REGION , 2021-2028 (USD MILLION)
TABLE 48 ASIA-PACIFIC BRONCHIECTASIS MARKET, BY COUNTRY, 2018-2028 (USD MILLION)
TABLE 49 ASIA-PACIFIC BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 50 ASIA-PACIFIC BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 51 ASIA-PACIFIC BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 52 ASIA-PACIFIC TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 53 ASIA-PACIFIC TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 54 ASIA-PACIFIC TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 55 ASIA-PACIFIC TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 56 ASIA-PACIFIC TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 57 ASIA-PACIFIC TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 58 ASIA-PACIFIC TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 59 ASIA-PACIFIC TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 60 ASIA-PACIFIC TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 61 ASIA-PACIFIC TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 62 ASIA-PACIFIC TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 63 ASIA-PACIFIC TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 64 ASIA-PACIFIC TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 65 ASIA-PACIFIC DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 66 ASIA-PACIFIC BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 67 ASIA-PACIFIC BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 68 ASIA-PACIFIC ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 69 ASIA-PACIFIC PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 70 ASIA-PACIFIC BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 71 ASIA-PACIFIC BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 72 JAPAN BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 73 JAPAN BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 74 JAPAN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 75 JAPAN TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 76 JAPAN TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 77 JAPAN TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 78 JAPAN TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 79 JAPAN TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 80 JAPAN TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 81 JAPAN TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 82 JAPAN TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 83 JAPAN TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 84 JAPAN TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 85 JAPAN TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 86 JAPAN TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 87 JAPAN TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 88 JAPAN DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 89 JAPAN BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 90 JAPAN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 91 JAPAN ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 92 JAPAN PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 93 JAPAN BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 94 JAPAN BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 95 CHINA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 96 CHINA BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 97 CHINA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 98 CHINA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 99 CHINA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 100 CHINA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 101 CHINA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 102 CHINA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 103 CHINA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 104 CHINA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 105 CHINA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 106 CHINA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 107 CHINA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 108 CHINA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 109 CHINA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 110 CHINA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 111 CHINA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 112 CHINA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 113 CHINA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 114 CHINA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 115 CHINA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 116 CHINA BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 117 CHINA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 118 INDIA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 119 INDIA BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 120 INDIA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 121 INDIA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 122 INDIA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 123 INDIA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 124 INDIA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 125 INDIA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 126 INDIA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 127 INDIA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 128 INDIA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 129 INDIA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 130 INDIA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 131 INDIA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 132 INDIA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 133 INDIA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 134 INDIA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 135 INDIA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 136 INDIA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 137 INDIA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 138 INDIA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 139 INDIA BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 140 INDIA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 141 AUSTRALIA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 142 AUSTRALIA BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 143 AUSTRALIA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 144 AUSTRALIA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 145 AUSTRALIA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 146 AUSTRALIA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 147 AUSTRALIA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 148 AUSTRALIA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 149 AUSTRALIA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 150 AUSTRALIA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 151 AUSTRALIA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 152 AUSTRALIA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 153 AUSTRALIA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 154 AUSTRALIA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 155 AUSTRALIA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 156 AUSTRALIA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 157 AUSTRALIA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 158 AUSTRALIA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 159 AUSTRALIA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 160 AUSTRALIA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 161 AUSTRALIA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 162 AUSTRALIA BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 163 AUSTRALIA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 164 SOUTH KOREA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 165 SOUTH KOREAT BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 166 SOUTH KOREA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 167 SOUTH KOREA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 168 SOUTH KOREA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 169 SOUTH KOREA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 170 SOUTH KOREA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 171 SOUTH KOREA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 172 SOUTH KOREA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 173 SOUTH KOREA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 174 SOUTH KOREA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 175 SOUTH KOREA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 176 SOUTH KOREA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 177 SOUTH KOREA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 178 SOUTH KOREA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 179 SOUTH KOREA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 180 SOUTH KOREA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 181 SOUTH KOREA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 182 SOUTH KOREA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 183 SOUTH KOREA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 184 SOUTH KOREA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 185 SOUTH KOREA BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 186 SOUTH KOREA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 187 SINGAPORE BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 188 SINGAPORE BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 189 SINGAPORE BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 190 SINGAPORE TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 191 SINGAPORE TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 192 SINGAPORE TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 193 SINGAPORE TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 194 SINGAPORE TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 195 SINGAPORE TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 196 SINGAPORE TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 197 SINGAPORE TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 198 SINGAPORE TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 199 SINGAPORE TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 200 SINGAPORE TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 201 SINGAPORE TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 202 SINGAPORE TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 203 SINGAPORE DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 204 SINGAPORE BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 205 SINGAPORE BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 206 SINGAPORE ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 207 SINGAPORE PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 208 SINGAPORE BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 209 SINGAPORE BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 210 MALAYSIA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 211 MALAYSIA BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 212 MALAYSIA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 213 MALAYSIA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 214 MALAYSIA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 215 MALAYSIA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 216 MALAYSIA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 217 MALAYSIA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 218 MALAYSIA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 219 MALAYSIA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 220 MALAYSIA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 221 MALAYSIA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 222 MALAYSIA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 223 MALAYSIA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 224 MALAYSIA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 225 MALAYSIA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 226 MALAYSIA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 227 MALAYSIA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 228 MALAYSIA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 229 MALAYSIA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 230 MALAYSIA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 231 MALAYSIA BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 232 MALAYSIA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 233 THAILAND BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 234 THAILAND BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 235 THAILAND BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 236 THAILAND TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 237 THAILAND TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 238 THAILAND TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 239 THAILAND TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 240 THAILAND TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 241 THAILAND TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 242 THAILAND TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 243 THAILAND TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 244 THAILAND TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 245 THAILAND TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 246 THAILAND TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 247 THAILAND TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 248 THAILAND TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 249 THAILAND DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 250 THAILAND BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 251 THAILAND BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 252 THAILAND ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 253 THAILAND PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 254 THAILAND BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 255 THAILAND BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 256 INDONESIA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 257 INDONESIA BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 258 INDONESIA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 259 INDONESIA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 260 INDONESIA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 261 INDONESIA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 262 INDONESIA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 263 INDONESIA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 264 INDONESIA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 265 INDONESIA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 266 INDONESIA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 267 INDONESIA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 268 INDONESIA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 269 INDONESIA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 270 INDONESIA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 271 INDONESIA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 272 INDONESIA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 273 INDONESIA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 274 INDONESIA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 275 INDONESIA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 276 INDONESIA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 277 INDONESIA BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 278 INDONESIA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 279 PHILIPPINES BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 280 PHILIPPINES BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 281 PHILIPPINES BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 282 PHILIPPINES TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 283 PHILIPPINES TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 284 PHILIPPINES TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 285 PHILIPPINES TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 286 PHILIPPINES TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 287 PHILIPPINES TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 288 PHILIPPINES TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 289 PHILIPPINES TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 290 PHILIPPINES TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 291 PHILIPPINES TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 292 PHILIPPINES TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 293 PHILIPPINES TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 294 PHILIPPINES TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 295 PHILIPPINES DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 296 PHILIPPINES BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 297 PHILIPPINES BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 298 PHILIPPINES ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 299 PHILIPPINES PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 300 PHILIPPINES BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 301 PHILIPPINES BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 302 VIETNAM BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 303 VIETNAM BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 304 VIETNAM BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 305 VIETNAM TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 306 VIETNAM TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 307 VIETNAM TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 308 VIETNAM TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 309 VIETNAM TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 310 VIETNAM TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 311 VIETNAM TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 312 VIETNAM TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 313 VIETNAM TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 314 VIETNAM TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 315 VIETNAM TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 316 VIETNAM TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 317 VIETNAM TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 318 VIETNAM DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 319 VIETNAM BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 320 VIETNAM BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 321 VIETNAM ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 322 VIETNAM PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 323 VIETNAM BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 324 VIETNAM BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 325 REST OF ASIA-PACIFIC BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
図表一覧
LIST OF FIGURES
FIGURE 1 ASIA PACIFIC BRONCHIECTASIS MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC BRONCHIECTASIS MARKET : DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC BRONCHIECTASIS MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC BRONCHIECTASIS MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC BRONCHIECTASIS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC BRONCHIECTASIS MARKET: MULTIVARIATE MODELLING
FIGURE 7 ASIA PACIFIC BRONCHIECTASIS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 ASIA PACIFIC BRONCHIECTASIS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA PACIFIC BRONCHIECTASIS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA PACIFIC BRONCHIECTASIS MARKET: MARKET DRUGS TYPE COVERAGE GRID
FIGURE 11 ASIA PACIFIC BRONCHIECTASIS MARKET: SEGMENTATION
FIGURE 12 RISING PATIENT POPULATION SUFFERING FROM BRONCHIECTASIS IS DRIVING THE ASIA PACIFIC BRONCHIECTASIS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 NON-CF BRONCHIECTASIS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC BRONCHIECTASIS MARKET IN 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA PACIFIC BRONCHIECTASIS MARKET
FIGURE 15 NUMBER OF PERSONS AGED 60 YEARS ACROSS SEVERAL REGIONS IN 2017 AND 2050
FIGURE 16 PREVALENCE OF BRONCHIECTASIS BY AGE IN KOREA POPULATION (2019)
FIGURE 17 HEALTH SPENDING BY MAJOR SOURCES OF FUNDS
FIGURE 18 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISEASE TYPE, 2021
FIGURE 19 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISEASE TYPE, 2019-2028 (USD MILLION)
FIGURE 20 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISEASE TYPE, CAGR (2021-2028)
FIGURE 21 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 22 ASIA PACIFIC BRONCHIECTASIS MARKET: BY SEVERITY, 2021
FIGURE 23 ASIA PACIFIC BRONCHIECTASIS MARKET: BY SEVERITY, 2019-2028 (USD MILLION)
FIGURE 24 ASIA PACIFIC BRONCHIECTASIS MARKET: BY SEVERITY, CAGR(2021-2028)
FIGURE 25 ASIA PACIFIC BRONCHIECTASIS MARKET: BY SEVERITY, LIFELINE CURVE
FIGURE 26 ASIA PACIFIC BRONCHIECTASIS MARKET: BY TYPE, 2021
FIGURE 27 ASIA PACIFIC BRONCHIECTASIS MARKET: BY TYPE, 2019-2028 (USD MILLION)
FIGURE 28 ASIA PACIFIC BRONCHIECTASIS MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 29 ASIA PACIFIC BRONCHIECTASIS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 30 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DRUGS TYPE, 2021
FIGURE 31 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DRUGS TYPE, 2019-2028 (USD MILLION)
FIGURE 32 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DRUGS TYPE, CAGR (2021-2028)
FIGURE 33 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DRUGS TYPE, LIFELINE CURVE
FIGURE 34 ASIA PACIFIC BRONCHIECTASIS MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 35 ASIA PACIFIC BRONCHIECTASIS MARKET: BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
FIGURE 36 ASIA PACIFIC BRONCHIECTASIS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)
FIGURE 37 ASIA PACIFIC BRONCHIECTASIS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 38 ASIA PACIFIC BRONCHIECTASIS MARKET: BY END USER, 2021
FIGURE 39 ASIA PACIFIC BRONCHIECTASIS MARKET: BY END USER, 2019-2028 (USD MILLION)
FIGURE 40 ASIA PACIFIC BRONCHIECTASIS MARKET: BY END USER, CAGR (2021-2028)
FIGURE 41 ASIA PACIFIC BRONCHIECTASIS MARKET: BY END USER, LIFELINE CURVE
FIGURE 42 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 43 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
FIGURE 44 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 45 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 46 ASIA PACIFIC BRONCHIECTASIS MARKET: SNAPSHOT (2020)
FIGURE 47 ASIA PACIFIC BRONCHIECTASIS MARKET: BY COUNTRY (2020)
FIGURE 48 ASIA PACIFIC BRONCHIECTASIS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 49 ASIA PACIFIC BRONCHIECTASIS MARKET: BY COUNTRY (2020 & 2028)
FIGURE 50 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISEASE TYPE (2021-2028)
FIGURE 51 ASIA-PACIFIC BRONCHIECTASIS MARKET: SNAPSHOT (2020)
FIGURE 52 ASIA-PACIFIC BRONCHIECTASIS MARKET: BY COUNTRY (2020)
FIGURE 53 ASIA-PACIFIC BRONCHIECTASIS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 54 ASIA-PACIFIC BRONCHIECTASIS MARKET: BY COUNTRY (2020 & 2028)
FIGURE 55 ASIA-PACIFIC BRONCHIECTASIS MARKET: BY DISEASE TYPE (2021-2028)
FIGURE 56 ASIA PACIFIC BRONCHIECTASIS MARKET: COMPANY SHARE 2020 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
